Circulating tumour DNA (ctDNA) is tumour-deriver fragmented DNA which originates either directly from the tumour or from circulating tumour cells. Identifying and quantifying ctDNA in patient blood can aid in detecting, diagnosing, and monitoring a tumour or can guide and assess the efficacy of tumour-specific treatments.
Analysis remains challenging for this type of molecule because it requires high sensitivity and selectivity for target genes.
In this webinar, Dr. Kurt Sales, Chief Scientific Officer at Agilex Biolabs, will discuss analytical hurdles and platform compatibility with ctDNA detection and quantification. Illustrating the importance of platform choice in a bioanalytical approach, Dr. Sales will present a case study of our successful detection of exon 15 (V600E) of the B-Raf proto-oncogene (BRAF) using Digital Droplet PCR (ddPCR™).
What will you learn?
- How circulating tumour DNA (ctDNA) is being used to uncover insights in drug development
- Current analytical challenges associated with ctDNA
- Applying Droplet Digital PCR (ddPCR™) technology to detect ctDNA
Who should attend?
- Industry professionals and scientists interested in gene therapy or advances in oncology research